New Jersey Innovation Institute (NJII) announced the sale of its subsidiary, BioCentriq Inc., to GC corp. for $73 million. BioCentriq manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.

Frantz Romain is the co-founder and CTO of PROFIT, a free banking and accounting solution for small businesses. He is also a 2016 NJIT graduate with a degree in Information Systems and a serious passion …

The digital transformation has hit the manufacturing floor. Learn more at the NJIT Industry 4.0 & Smart Manufacturing panel discussion.

The digital transformation has hit the manufacturing floor. Learn more at the NJIT Industry 4.0 & Smart Manufacturing panel discussion.

The digital transformation has hit the manufacturing floor. Learn more at the NJIT Industry 4.0 & Smart Manufacturing panel discussion.

The digital transformation has hit the manufacturing floor. Learn more at the NJIT Industry 4.0 & Smart Manufacturing panel discussion.

The digital transformation has hit the manufacturing floor. Learn more at the NJIT Industry 4.0 & Smart Manufacturing panel discussion.

New Jersey Innovation Institute (NJII) announced today that it has joined the Strategic Health Information Exchange Collaborative (SHIEC).

NJII announces partnership with McKinsey & Company in the launch of a new center to advance operations and manufacturing excellence in cell and gene therapy (CGT).

Around the world, developments in automation and mechanization are being introduced to a new wave of technological revolution.

Diverse organizations are more profitable on average than non-diverse organizations – an added incentive for companies to take DEI more seriously.

NJII Sits on TechLaunch BullPen 21 Panel. The Bullpen is a part of TechLaunch’s Business Accelerator program intended for seed stage entrepreneurs to present their startup companies.